• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Christopher Sweeney, MBBS


  • Valenca LB, Sweeney CJ, Pomerantz MM.
    Sequencing current therapies in the treatment of metastatic prostate cancer.
    Cancer Treat Rev. 2015 Apr;41(4):332-340.
  • Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.
    Risk of Prostate Cancer Mortality in Men with a History of Prior Cancer.
    BJU Int. 2015 Apr 4.
  • Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF, Trinh QD, Nguyen PL.
    Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?.
    Am J Med. 2015 Jan 30.
  • Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW.
    PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration Resistant Prostate Cancer, is a Mediator of Resistance to Androgen Deprivation Therapy.
    Cancer Res. 2015 Mar 25.
  • Pal SK, Azad AA, Bhatia S, Drabkin HA, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub AN, Hauke RJ, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske AF, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson TE.
    A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC.
    Clin Cancer Res. 2015 Mar 18.
  • Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA, .
    The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
    Prostate. 2015 Mar 1.
  • Bernard B, Sweeney CJ.
    Management of metastatic hormone-sensitive prostate cancer.
    Current Urology Reports. 2015 Mar;16(3):14.
  • Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.
    Incidence and Predictors of Upgrading and Upstaging Among 10,000 Contemporary Patients with Low-risk Prostate Cancer.
    J Urol. 2015 Feb 10.
  • Zukotynski KA, Kim CK, Gerbaudo VH, Hainer J, Taplin ME, Kantoff P, den Abbeele AD, Seltzer S, Sweeney CJ.
    (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.
    Am J Nucl Med Mol Imaging. 2015;5(1):72-82.
  • Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA.
    SPINK1 Protein Expression and Prostate Cancer Progression.
    Clin Cancer Res. 2014 Mar 31.
  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL.
    Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer.
    Journal Of Geriatric Oncology. 2014 May 23.
  • Mahal BA, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Hoffman KE, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Trinh QD, Nguyen PL.
    Racial Disparities in Prostate Cancer-Specific Mortality in Men With Low-Risk Prostate Cancer.
    Clin Genitourin Cancer. 2014 May 9.
  • Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, Balk S, Lee GS, Kantoff PW.
    MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.
    Oncogene. 2014 May 22(21):2790-800.
  • Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CJ, Lee GS, Chen S, Balk SP, Liu XS, Brown M, Kantoff PW.
    Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation.
    Proc Natl Acad Sci U S A. 2014 May 20(20):7319-24.
  • Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Sammon JD, Schmid M, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D׳Amico AV, Martin NE, Lathan C, Kim SP, Trinh QD, Nguyen PL.
    Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.
    Urol Oncol. 2014 May 17.
  • Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, Bubley GJ, Stack EC, Signoretti S, Walsh M, Steele G, Hirsch M, Sweeney CJ, Taplin ME, Kibel AS, Krajewski KM, Kantoff PW, Ross RW, Rosenberg JE.
    Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates.
    J Clin Oncol. 2014 May 12.
  • Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.
    Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
    Prostate. 2014 Jun;74(8):820-8.
  • Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL.
    Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?.
    Urology. 2014 Apr 8.
  • Basch EM, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI.
    Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort.
    Eur Urol. 2014 Feb 20.
  • Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R.
    A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
  • Hahn NM, Yiannoutsos CT, Kirkpatrick K, Sharma J, Sweeney CJ.
    Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
    Clin Genitourin Cancer. 2014 Feb;12(1):33-40.e4.
  • Sweeney CJ.
    Preface. Prostate cancer.
    Hematol Oncol Clin North Am. 2013 Dec;27(6):xi-xii.
  • Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ.
    Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.
    Prostate. 2013 Oct 16.
  • Nichols CR, Roth B, Albers P, Einhorn LH, Foster R, Daneshmand S, Jewett M, Warde P, Sweeney CJ, Beard C, Powles T, Tyldesley S, So A, Porter C, Olgac S, Fizazi K, Hayes-Lattin B, Grimison P, Toner G, Cathomas R, Bokemeyer C, Kollmannsberger C.
    Active surveillance is the preferred approach to clinical stage I testicular cancer.
    J Clin Oncol. 2013 Oct 1;31(28):3490-3.
  • Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.
    Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.
    Cancer. 2013 Aug 15;119(16):2990-8.
  • Sweeney C.
    Prostate cancer therapy: going forwards by going backwards.
    Lancet Oncol. 2013 Feb;14(2):104-5.
  • Nguyen PL, Devlin PM, Beard CJ, Orio PF, O'Leary MP, Wolfsberger LD, O'Farrell DA, Sweeney CM, Hadaschik BA, Hohenfellner M, Hatiboglu G.
    High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: case report and review of the literature.
  • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.
    Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
    J Clin Oncol. 2012 Nov 19.
  • Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC.
    Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
    Nanomed. 2012 Oct 17.
  • Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon A, Suppan C, Flavin R, Sesso H, Rider JR, Sweeney CS, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci E, Ding EL, Loda M, Mucci LA.
    The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: a Cohort Study and Meta-analysis.
    Cancer Epidemiol Biomarkers Prev. 2012 Jun 26.
  • Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S.
    Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
    Sci Transl Med. 2012 Apr 4;4(128):128ra39.
  • Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ.
    Barriers to the Implementation of Surveillance for Stage I Testicular Seminoma.
    Int J Radiat Oncol Biol Phys. 2012 Feb 18.
  • Estabrook NC, Chin-Sinex H, Borgmann AJ, Dhaemers RM, Shapiro RH, Gilley D, Huda N, Crooks P, Sweeney C, Mendonca MS.
    Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays.
    Free Radic Biol Med. 2011 Dec 15;51(12):2249-58.
  • Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA.
    Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
    Invest New Drugs. 2011 Nov 12.
  • Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG.
    Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer.
    J Urol. 2011 Sep;186(3):865-72.
  • Patel YR, Carr KA, Magjuka D, Mohammadi Y, Dropcho EF, Reed AD, Moore ML, Waddell MJ, Shedd-Steele R, Sweeney CJ, Hahn NM.
    Successful recruitment of healthy African American men to genomic studies from high-volume community health fairs: Implications for future genomic research in minority populations.
    Cancer. 2011 Jul 15.
  • Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ.
    Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75.
    J Clin Oncol. 2011 Apr 20;29(12):1525-30.
  • Shanmugam R, Kusumanchi P, Appaiah H, Cheng L, Crooks P, Neelakantan S, Peat T, Klaunig J, Matthews W, Nakshatri H, Sweeney CJ.
    A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species.
    Int J Cancer. 2011 May 15;128(10):2481-94.
  • Resta LP, Pili R, Eisenberger MA, Spitz A, King S, Porter J, Franke A, Boinpally R, Carducci MA, Sweeney CJ.
    A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
    Cancer Chemother Pharmacol. 2011 Feb;67(2):431-8.
  • Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M.
    Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
    Clin Cancer Res. 2011 Jan 15;17(2):363-71.
  • Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ.
    Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610.
    BJU Int. 2010 Dec 13.
  • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.
    Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.
    JAMA. 2010 Dec 1;304(21):2373-80.
  • Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA.
    A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
    J Clin Oncol. 2010 Oct 10;28(29):4513-20.
  • Chiorean EG, Malireddy S, Younger AE, Jones DR, Waddell MJ, Sloop MI, Yu M, Hall SD, Schneider B, Sweeney CJ.
    A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2010 Aug;66(3):441-8.
  • Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, Nakshatri H, Sweeney CJ.
    A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappaB and generating reactive oxygen species.
    Prostate. 2010 Jul 1;70(10):1074-86.
  • Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G.
    A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
    Invest New Drugs. 2010 May 25.
  • Sweeney CJ, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M, D'Andrea DM, Remick SC.
    A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
    Cancer Chemother Pharmacol. 2010 Jul;66(2):345-56.
  • Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, Shubhakar P, Zhu M, Oliner KS, Anderson A, Yee LK.
    A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
    Clin Cancer Res. 2010 May 1;16(9):2677-87.
  • Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.
    Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Clin Cancer Res. 2010 Jan 15;16(2):699-710.